Founded

Address

Clarus Ventures LLC
One Memorial Drive
Suite 1230
Cambridge, MA 02142
United States

Open map


Recent investment activity

KANDO id: 30972

Corporate information

Official name
Clarus Ventures LLC
Registration country

Company type

Life sciences venture capital firm

Funds managed

Fund Type Vintage Currency Committed capital IRR x
Clarus IV-A LP Venture 2017 USD 789,700,000
Clarus IV-B LP Venture 2017 USD 789,700,000
Clarus IV-C LP Venture 2017 USD 789,700,000
Clarus IV-D LP Venture 2017 USD 789,700,000
Clarus DE II LP Venture 2014 USD 40,000,000
Clarus Defined Exit I LP Venture 2014 USD 100,000,000
Clarus Lifesciences III LP Venture 2014
Clarus Ventures III GP LP Venture 2014
Clarus Lifesciences II LP Venture 2008 USD 14.80 % 1.80 x
Clarus Lifesciences I LP Venture 2006 USD 3.90 % 1.20 x
Clarus Ventures II Venture USD 697,000,000

Funding rounds

Profile Country Notes
The Blackstone Group LP Private equity firm Led the round.

Investment preferences


Investment activity status
Not investing

Selected investments

Displaying 1 - 38 of 38
Profile Country Date Funding
Avanir Pharmaceuticals Inc A biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. N/A
Catabasis Pharmaceuticals Inc Series A
Catabasis Pharmaceuticals Inc Series A
Cellerant Therapeutics Inc Biotechnology company with a portfolio of products based on the regulation of the hematopoietic (blood-forming) system. N/A
CoMentis Inc N/A
Delenex Therapeutics AG N/A
Edev N/A
ESBATech AG Switzerland based Biomedical Research Unit of Alcon Series B
ESBATech AG Switzerland based Biomedical Research Unit of Alcon Series B
FerroKin Biosciences Inc A clinical stage biotechnology company dedicated to improving the management of patients with iron overload. N/A
Flowonix Medical A medical device company dedicated to helping those who suffer from chronic disorders. N/A
Globus Medical Inc A medical device company, focuses on the design, development, and commercialization of products that promote healing in patients with spine disorders. Series E
Heptares Therapeutics Ltd Series A
Link Medicine Inc Advancing disease-modifying technologies targeted at Alzheimer's, Parkinson's and other neurodegenerative diseases Series C
Lycera Corp Series A
Pearl Therapeutics Inc Developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases N/A
Pearl Therapeutics Inc Developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases N/A
Proacta Inc Series B
SARcode Bioscience Inc Series B
Sientra Inc Medical device company Series C
Taligen Therapeutics Inc N/A
TyRx Inc N/A
TyRx Inc N/A
VBI Vaccines Inc A biotechnology company, engages in the formulation, development, and delivery of vaccines in the United States and internationally. N/A
Virdante Pharmaceuticals Inc A privately held biopharmaceutical company focused on the development and commercialization of drugs for autoimmune and inflammatory disorders. Series A
Zogenix Inc A pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. N/A
Zogenix Inc A pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Series B
Achillion Pharmaceuticals Inc Biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. N/A
Aerie Pharmaceuticals Inc Series B
Aerovance Inc Series C
Aerovance Inc N/A
Biolex Therapeutics Inc Series D
Cleave Biosciences Inc Drug development company focused on novel targets in cellular protein homeostasis pathways Series A
NanoString Technologies Inc A life sciences company, markets solutions for detecting and counting large sets of target molecules in biological samples for researchers. Series C
NanoString Technologies Inc A life sciences company, markets solutions for detecting and counting large sets of target molecules in biological samples for researchers. Series D
Oxford Immunotec Ltd Series C led the round
Oxford Immunotec Ltd Series D
Oxford Immunotec Ltd Venture

Current team

Current team

Financials